A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Wednesday, March 6, 2013
Mantle Cell Lymphoma
*In Mantle cell lymphoma, Rituxan-Bendamustine beats R-CHOP
with progression free survival of 69 months vs 31 months and with better toxicity profile
except for skin erythematous lesion often seen with Bendamustine.
No comments:
Post a Comment